Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

3.134.83.74
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Autoimmune PAP
Interstitial Lung Disease
Journal Scan

YKL-40 a potential biomarker for diagnosis, prognosis of ILD

Posted on

YKL-40 may potentially be used as a biomarker for the diagnosis and prognosis of patients with interstitial lung disease (ILD), according to a study.

-Advertisement-
-Advertisement-

In this systematic review and meta-analysis of 16 articles on the role of YKL-40 in patients with ILD, serum YKL-40 levels were higher in patients with idiopathic pulmonary fibrosis, connective tissue-related ILD, sarcoidosis, cryptogenic tissue pneumonia, asbestosis-ILD, and idiopathic nonspecific interstitial pneumonia than controls. In patients with pulmonary alveolar proteinosis, YKL-40 levels were not higher.

Patients with different types of ILD also had different serum YKL-40 levels, the researchers said, noting that patients with idiopathic pulmonary fibrosis had significantly higher bronchoalveolar lavage fluid YKL-40 levels than controls. A systematic review also showed a correlation between serum YKL-40 levels and lung function in different types of ILD.

“In addition, YKL-40 may be used as a valuable biomarker for survival, with risk ratios ranging from 1.006 to 10.9,” the authors concluded.

Reference
Tong X, Ma Y, Liu T, et al. Can YKL-40 be used as a biomarker for interstitial lung disease?: A systematic review and meta-analysis. Medicine (Baltimore). 2021;100(17):e25631. doi: 10.1097/MD.0000000000025631. PMID: 33907118.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-